New telmisartan approvals for Boehringer Ingelheim
This article was originally published in Scrip
Executive Summary
The US FDA has approved an expanded indication for Boehringer Ingelheim's antihypertensive, telmisartan. It has also approved Twynsta, a combination product containing the angiotensin II receptor blocker (ARB) and amlodipine, a calcium channel blocker.